
In the last ten years, the development of several novel targeted drugs and the refinement of state of the art technologies such as the zzso and zzso and their introduction to clinical practice have revolutionized the management of patients affected by zzso However, everyday practice points out several clinical questions: the difficulty of response assessment to new drugs especially using standard zzso criteria that do not provide information on zzso vascular or zzso zzso the inadequate selection of patients who are likely to benefit from a targeted therapy excluding those with breast cancer and gastrointestinal zzso zzso the need to know the global biological background of diseases especially in zzso setting using zzso zzso zzso zzso imaging could provide information on in zzso distribution of biological markers in response to targeted therapy and could improve the selection of patients before zzso The aim of this review is to analyze the current role of conventional and innovative zzso zzso zzso zzso zzso in clinical practice and to explore the promising perspectives of molecular imaging in cancer zzso 

